On June 28, Senseonics also released the PROMISE Study data for Eversense CGM (continuous glucose monitoring) at the American Diabetes Association Virtual 81st Annual Scientific Sessions. The stock is rising after the data release because investors are bullish on the results. Jim Cramer on Senseonics stock
Full Answer
Is Senseonics a good stock to invest?
Will Senseonics go up?
Is Senseonics overvalued?
Should I sell Senseonics stock?
Will Bionano Genomics stock go up?
The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +469.40% increase from the last price of 1.41.
Is Senseonics FDA approved?
What does Senseonics Holdings Inc do?
Is SENS a good stock?
Is SENS a long term hold?
Is Senseonics a buy right now?
Who are Senseonics competitors?
- Intuity Medical. $33 Million.
- DarioHealth. $7 Million.
- Bionime. 917. $65 Million.
- AgaMatrix. 400. $25 Million.
- Sotera Wireless. 113. $22 Million.
- Roche Diabetes Care. 144. $27 Million.
- Synaptive Medical. 160. $40 Million.
- Adams County Courthouse. 345. -
Is Jim Cramer optimistic about Senseonics?
CNBC Mad Money host Jim Cramer isn't too optimistic on Senseonics stock. He sees the stock as speculative and said that the company competes with the likes of Abbott and Dexcom. Both of these companies are much larger rivals with deep pockets.
Who makes Eversense CGM?
Senseonics produces the Eversense CGM (continuous glucose monitoring). The market for diabetic care is expected to rise sharply given the growing number of cases. If SENS can successfully commercialize Eversense, it will be a gamechanger for the company whose current market capitalization is only around $1.6 billion.
Shares jump after the company receives some favorable commentary from a Wall Street analyst
Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here. Follow @brianferoldi
What happened
After receiving a buy rating and an upbeat price target from a Wall Street analyst, shares of Senseonics Holdings ( NYSEMKT:SENS), a small-cap medical device company focused on glucose-monitoring solutions for people with diabetes, jumped as much as 10% in afternoon trading on Wednesday. Shares were up 9% as of 3:05 p.m. EDT.
So what
Senseonics bulls can thank Christopher Pasquale from Guggenheim for today's jump. Pasquale reiterated his buy rating on the company's stock and also set a price target of $6 per share. That represents an almost exact double from yesterday's closing price of about $3 per share.
Now what
Senseonics shareholders have enjoyed a prosperous 2018 thus far. The company shored up its balance sheet in January by raising about $48 million through a convertible note offering.
What happened
After receiving a buy rating and an upbeat price target from a Wall Street analyst, shares of Senseonics Holdings (NYSEMKT: SENS), a small-cap medical device company focused on glucose-monitoring solutions for people with diabetes, jumped as much as 10% in afternoon trading on Wednesday. Shares were up 9% as of 3:05 p.m. EDT.
So what
Senseonics bulls can thank Christopher Pasquale from Guggenheim for today's jump. Pasquale reiterated his buy rating on the company's stock and also set a price target of $6 per share. That represents an almost exact double from yesterday's closing price of about $3 per share.
Now what
Senseonics shareholders have enjoyed a prosperous 2018 thus far. The company shored up its balance sheet in January by raising about $48 million through a convertible note offering.
What happened
After receiving a buy rating and an upbeat price target from a Wall Street analyst, shares of Senseonics Holdings (NYSEMKT: SENS), a small-cap medical device company focused on glucose-monitoring solutions for people with diabetes, jumped as much as 10% in afternoon trading on Wednesday. Shares were up 9% as of 3:05 p.m. EDT.
So what
Senseonics bulls can thank Christopher Pasquale from Guggenheim for today's jump. Pasquale reiterated his buy rating on the company's stock and also set a price target of $6 per share. That represents an almost exact double from yesterday's closing price of about $3 per share.
Now what
Senseonics shareholders have enjoyed a prosperous 2018 thus far. The company shored up its balance sheet in January by raising about $48 million through a convertible note offering.
What is Eversense XL?
Using its continuous glucose monitoring (CGM) systems, called Eversense and Eversense XL, the company aims to aid disease management for many of the hundreds of millions of diabetes sufferers internationally.
What is etoro trading?
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
